Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean glycol and methyl?
Displaying drugs 476 - 500 of 15425 in total
Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
Approved
Investigational
Matched Iupac: … 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine …
Matched Description: … Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. …
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Iupac: … 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide …
Matched Description: … Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like …
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
Matched Iupac: … N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(2E)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent- …
Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Approved
Matched Iupac: … 2'-yl)methyl](carboxymethyl)amino}acetic acid ... 2-{[(7'-{[bis(carboxymethyl)amino]methyl}-3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]- …
Matched Description: … It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. …
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s....
Approved
Investigational
Matched Description: … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation …
Matched Categories: … pindolol and other diuretics …
A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including...
Approved
Vet approved
Matched Description: … Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation …
Matched Categories: … Genito Urinary System and Sex Hormones ... Topical Products for Joint and Muscular Pain …
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA...
Approved
Investigational
Matched Iupac: … {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid …
Matched Description: … [A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis. ... third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and
Matched Categories: … ibandronic acid and colecalciferol ... Drugs Affecting Bone Structure and Mineralization …
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Iupac: … (2S)-2-[({4-[(3-fluorophenyl)methoxy]phenyl}methyl)amino]propanamide …
Matched Description: … It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Approved
Matched Iupac: … 1-({[2-(propanoyloxy)ethyl]carbamoyl}methyl)pyridin-1-ium chloride …
Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Approved
Withdrawn
Matched Iupac: … 7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one …
Matched Description: … Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due …
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Approved
Investigational
Matched Iupac: … (1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo …
Matched Description: … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently …
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Iupac: … ]-7-[(1H-indol-3-yl)methyl]-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane ... diaminomethylidene)amino]-2-acetamidopentanamido]-10-{3-[(diaminomethylidene)amino]propyl}-16-[(1H-imidazol-5-yl)methyl
Matched Description: … [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval ... agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Iupac: … 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide …
Matched Categories: … Benzamides and benzamide derivatives …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Iupac: … ethyl N-(2-amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)carbamate …
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.
Approved
Matched Iupac: … N-benzyl-N-[(4,5-dihydro-1H-imidazol-2-yl)methyl]aniline …
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Iupac: … hexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium …
Matched Description: … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular ... Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... debris and exudate, thereby promoting tissue contact of the administered medication. …
Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
Approved
Matched Iupac: … N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine …
Matched Description: … Thonzylamine is an antihistamine and anticholinergic drug. …
Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure .
Approved
Matched Iupac: … 6-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶-benzothiopyran-7-sulfonamide …
Matched Description: … It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647 …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Iupac: … iron(3+) tris(2-methyl-4-oxo-4H-pyran-3-olate) …
Matched Description: … bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and
Matched Categories: … Blood and Blood Forming Organs …
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis . Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Iupac: … 1-methyl-2-[(E)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine …
Matched Description: … Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and ... Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% ... infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Iupac: … -(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate ... propan-2-yl 2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)phenyl)amino]-4 …
Matched Description: … typically associated with a poorer prognosis (as compared to "classical" _EGFR_ mutants causing NSCLC) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Approved
Investigational
Matched Mixtures name: … Normosol-M and Dextrose ... Plasma-lyte 56 and Dextrose ... Normosol-M and Dextrose …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Iupac: … 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo- …
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Iupac: … N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3 …
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Iupac: … )phenyl]methyl}-1,4-diazabicyclo[2.2.2]octan-1-ium ... dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1lambda6-benzothiepin-5-yl]phenoxy}methyl
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor ... [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also ... were treated with antihistamines, [rifampin], [ursodeoxycholic acid], [cholestyramine], [naltrexone], and
Matched Categories: … Bile and Liver Therapy ... Alimentary Tract and Metabolism …
Displaying drugs 476 - 500 of 15425 in total